Clinical Trial Search

Primary: Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24) — -473.7; -322.3 units…

Primary: Percentage of Treated Patients With an Average Serum Testosterone (T) Concentration (Cavg) Between 300 and 1000 ng/dL — 87 Participants

Primary: Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks — 12; 10 Participants

Primary: American College of Rheumatology (ACR) 20 Response Rate — 72.5; 74.3 Percentage of participants

Primary: The Percentage of Subjects on Day 90 Whose Cavg (0-24) Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL — 2.9; 4.7; 77.9; 85.5 percentage of participants

Primary: Modified Intent-to-Treat (mITT) Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic Deep Vein Thrombosis (DVT), Non-fatal Pulmonary…

Primary: Percentage of Participants With Apheresis Avoidance at the End of Randomized Therapy — 10.0; 84.2 percentage of participants — p=< 0.0001

Primary: Change in Cognition — 0.13; 0.47; 0.18 units on a scale — p=0.9591

Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at Week 12 — 25.1; 27.6; 27.2 Percentage of participants — p=0.546

Primary: Time to First Confirmed Worsening on the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale — 721.0; 540.0 Days — p=0.9838

Primary: Overall Survival (OS) — 11.86; 10.22 Months — p=0.1044

Primary: Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 Weeks — -0.623; -1.433; -1.455 counts/day — p=< 0.001

Primary: Number of Participants With Treatment Failure — 15; 24 Participants — p=0.0185

Primary: Assessment Of Participant's Ability To Use The SSEC — 1; 2; 10; 48 participants

Primary: Change in HbA1c From Baseline to Week 28 — -0.96; -0.22 Percentage of HbA1c — p=<0.001